SWOG clinical trial number
SWOG-9205

Central Prostate Cancer Serum Repository Protocol

Closed
Phase
Abbreviated Title
Ancillary Prostate
Activated
10/01/1992
Closed
10/01/2006
Participants
NCORP, Members, UCOP, Medical Oncologists, Surgeons, Pathologists, Affiliates

Research committees

Genitourinary Cancer

Eligibility Criteria Expand/Collapse

Pt must be eligible for and registered to a SWOG protocol for carcinoma of the prostate. Pts must submit greater than/equal to 3 ml of unthawed serum from baseline.

Other Clinical Trials

SWOG Clinical Trial Number
S2419

Phase II/III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic MO-03, or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma (BioFront Trial)
Research Committee(s)
Genitourinary Cancer
Activated
04/22/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2427

Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Research Committee(s)
Genitourinary Cancer
Activated
09/04/2025
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
CCTG-PR26

A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Research Committee(s)
Genitourinary Cancer
Activated
01/30/2025
Open
Phase